Antares Pharma Inc: (NASD: ATRS)

$3.96

-0.10 (-2.46%)

Volume 1,460,249

May 22 04:00 PM ET

Zacks Rank: 4-Sell

Zacks Rank	Definition	Annualized Return
#1	Strong Buy	26.6%
#2	Buy	18.71%
#3	Hold	10.12%
#4	Sell	4.32%
#5	Strong Sell	2.16%
S&P	500	9.93%

Overview Quote

            Stock Activity
        
		Day Low - High
		3.94 - 4.14
	
		52wk Low - High
		2.60 - 5.58
	
		Previous Close
		4.06
	
		Avg. Volume
		1,073,220
	
		Industry
		MED/DENTAL-SUPP
	
		Market Cap
		512.25 M
	
		Div - Yield
		0.00 - 0.00
	
		Beta
		0.75
	
		PE (Forward)
		0.00
	
		Current Year Est.
		-0.10
	
		Quarterly Earnings ESP 
		33.33%
	
Earnings ESP (Expected Surprise Prediction) is Zacks' proprietary methodology for determining which stocks have the best chance to surprise with their next earnings announcement. The Earnings ESP shows the percentage difference between the Most Accurate Estimate and the Consensus.

                Premium research
            
		Zacks Rank  Short-Term: 1-3 Months
                                                                
                                                                Zacks #1 Rank Strong Buys
                                                                
                                                            This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below. 

                                                                        Zacks Rank
                                                                        Definition
                                                                        Annualized Return
                                                                    
                                                                        #1
                                                                        Strong Buy
                                                                        26.6%
                                                                    
                                                                        #2
                                                                        Buy
                                                                        18.71%
                                                                    
                                                                        #3
                                                                        Hold
                                                                        10.12%
                                                                    
                                                                        #4
                                                                        Sell
                                                                        4.32%
                                                                    
                                                                        #5
                                                                        Strong Sell
                                                                        2.16%
                                                                    
                                                                        S&P
                                                                        500
                                                                        9.93%
                                                                    
Zacks Rank Education - Learn more about the Zacks Rank
Zacks Rank Home - All Zacks Rank resources in one place
Zacks Premium - The only way to get access to the Zacks Rank
                                                        
		4
Sell

		Zacks Recommendation  Long-Term: 6+ Months
                                                                
                                                                All Outperform Rated Stocks
                                                                
                                                            Zacks Recommendations are an excellent predictor of stock price movement over a 6+ month time frame. The recommendations come from the Zacks Equity Research group which combines the Zacks Rank with the insights from their team of over 50 equity analysts. The result is superior long term stock ratings.
The Zacks Recommendations are split into 3 groups: Buy, Hold and Sell. Our Buy recommendations have generated returns of 34.4% in 2006, and 16.69% in 2007. When Zacks Premium members click on the recommendation it will launch them to the Zacks Equity Research report for the stock.    More on these reports below.

                                                                    Difference Between Zacks Rank and Zacks Recommendation

                                                                    Zacks Equity Research Home
Zacks Premium - The only way to get access to Zacks Recommendations
                                                                
		Neutral
	
		Zacks Industry Rank Which industries are set to outperform or underperform the market? You'll find the answer here. We have broken down all industries into over 200 classifications. Then ranked these industries using the most powerful indicator we know (the Zacks Rank). The higher the industry rank, the better the industry should perform in the future. Once you have found an attractive industry then check out the Rank in Industry to find the best stocks within the industry.
When Zacks Premium members click on the Zacks Industry Rank link they will see the full listing of industries and their current rankings.

                                                                About Zacks Industry Rank

                                                                Zacks Industry Rank - All current industry ranks. 

                                                                Zacks Premium - The only way to get access to the Zacks Industry Rank
                                                            
		119 out of 265
	
		Equity Research Report The Zacks Recommendations and Zacks Target Prices are just two of the valuable resources you'll find in the reports created by the Zacks Equity Research group. When Zacks Premium members click on this link they will taken to a page that gives them access to the Zacks Equity Research report for the stock.

                                        Zacks Equity Research Home
                                        Zacks Premium - The only way to get access to Zacks Recommendations
                                    
Updated as of 05/17/2013

		PREMIUM
	
    (  = Change in last 30 days) 
Get all our stock ratings and recommendations with a Free Trial to Zacks Premium Start Free Trial 
Zacks Premium Home | Zacks Rank Stock Education

                Key Earnings Data
            
                            PE (Forward)
                            NA
                        
                            PEG Ratio
                            NA
                        
                            Current Year Est.
                            -0.10
                        
                            Current Quarter Estimate
                            -0.03
                        
                            Most Accurate Estimate
                            -0.02
                        
                            Earnings ESP 
                            33.33%
                        
                            Next Earnings Report Date
                            08-07-2013
                        
                            EPS Last Year
                            -0.13
                        
                            Expected Earnings Growth
                            NA
                        
Earnings ESP (Expected Surprise Prediction) is Zacks' proprietary methodology for determining which stocks have the best chance to surprise with their next earnings announcement. The Earnings ESP shows the percentage difference between the Most Accurate Estimate and the Consensus.

            Company Description
        
Antares Pharma, Inc. develops, commercializes and markets novel delivery solutions, including needle-free and mini-needle injector systems, gel technologies and transdermal products, which improve both the efficiency of drug therapies and the quality of life for patients. The Company currently distributes its needle-free injector systems for the delivery of insulin and growth hormone in over 20 countries and an estradiol transdermal patch for hormone replacement therapy.   
Full ATRS Company Report

        
NYSE data is at least 20 minutes delayed.
NASDAQ data is at least 15 minutes delayed.

            Interactive Java Charting | Fundamental Charts
        
            <a href="#"><img id="dart_image_1" src="http://b7d61a7c6b8c307bf531-a92a66b9587e2a0aa805bd4e70b98407.r95.cf2.rackcdn.com/images/zacks/logos/zacks_logo_230x76.png" width="336" height="280" border="0" alt="" /></a>        
Turn Earnings Surprises into quick profits.
 
ATRS Chart  by YCharts

Earnings Estimates

	Current Qtr (06/2013)	Next Qtr (09/2013)	Current Year (12/2013)	Next Year (12/2014)
Average Estimate	-0.03	-0.03	-0.10	0.02
Number of Estimates	3	3	3	3
Low Estimate	-0.03	-0.04	-0.11	-0.12
High Estimate	-0.02	-0.02	-0.10	NA
Year Ago EPS	-0.03	-0.03	-0.10	-0.10
EPS Growth	11.11%	0.00%	-3.33%	119.35%

More ATRS Estimates

Average Earnings Estimates for ATRS

EPS Growth for ATRS

Industry Analysis

Name	Symbol	Previous Close
ANTARES PHARMA	ATRS	4.06
LUXOTTICA ADR	LUX	53.97
ALPHATEC HLDGS	ATEC	1.95
CONMED CORP	CNMD	33.24
COOPER COS	COO	110.99
MWI VET SUPPLY	MWIV	120.38
STERIS CORP	STE	45.99
WEST PHARM SVC	WST	68.41
ALIGN TECH INC	ALGN	38.16
BARD C R INC	BCR	106.71

Sector:Medical>> Industry:MED/DENTAL-SUPP

COMPARE TICKER vs. Its Peers

Zacks Commentary

Company News for March 14, 2013

Mar 14, 2013

Zacks Rank #5 Additions for Wednesday

Mar 06, 2013

Zacks Rank #5 Additions for Monday

Mar 04, 2013

Zacks Rank #5 Additions for Monday

Feb 25, 2013

Zacks Rank #5 Additions for Wednesday

Feb 20, 2013

Zacks Rank #5 Additions for Thursday

Feb 07, 2013

Zacks #5 Rank Additions for Friday

Jan 11, 2013

Zacks #5 Rank Additions for Friday

Jan 04, 2013

More ATRS Zacks Commentary

Financials

EPS TTM	-0.13
Sales	23
Net Income	-15
Price/Earnings	NA
Price/Book	6.13
Price/Cash Flow	NA
Price/Sales	25.31

More ATRS Financials

News

Antares Pharma Q1 net loss increases - Datamonitor

May 22, 2013

2013 FDA Drug Approval Calendar - TheStreet.com

May 21, 2013

Antares Pharma Releases 1Q 2013 Operating and Financial Results - Close-Up Media

May 12, 2013

Antares Pharma Inc.Corporate Event Announcement Notice - Wall Street Horizon

May 9, 2013

Antares Pharma to Present at the Bank of America Merrill Lynch 2013 Healthcare Conference - Businesswire

May 9, 2013

Antares Pharma Inc.Corporate Event Announcement Notice - Wall Street Horizon

May 8, 2013

Antares Pharma Reports First Quarter 2013 Operating and Financial Results - Businesswire

May 8, 2013

Antares Pharma has the Highest Revenue Per Employee in the Health Care Supplies Industry (AIS, VIVO, CERS) - Financial News Network Online - News Corner

May 8, 2013

See All News Stories on ATRS

Broker Recommendations

Current ABR	1.00
ABR (Last Week)	1.00
# of recs in ABR	4
Average Target Price	5.00
Industry Rank by ABR	119 out of 265
Rank in Industry	24 out of 29

More ATRS Broker Recommendations

Day Low - High	3.94 - 4.14
52wk Low - High	2.60 - 5.58
Previous Close	4.06
Avg. Volume	1,073,220
Industry	MED/DENTAL-SUPP
Market Cap	512.25 M
Div - Yield	0.00 - 0.00
Beta	0.75
PE (Forward)	0.00
Current Year Est.	-0.10
Quarterly Earnings ESP	33.33%

PE (Forward)	NA
PEG Ratio	NA
Current Year Est.	-0.10
Current Quarter Estimate	-0.03
Most Accurate Estimate	-0.02
Earnings ESP	33.33%
Next Earnings Report Date	08-07-2013
EPS Last Year	-0.13
Expected Earnings Growth	NA

Username: Password:

Remember me [?]

Antares Pharma Inc: (NASD: ATRS)

$3.96

-0.10 (-2.46%)

Volume 1,460,249

May 22 04:00 PM ET

Stock Activity

Premium research

Zacks Rank Short-Term: 1-3 Months

Zacks Recommendation Long-Term: 6+ Months

Zacks Industry Rank

Equity Research Report

Key Earnings Data

Company Description

Earnings Estimates

Industry Analysis

Sector:Medical>> Industry:MED/DENTAL-SUPP

Zacks Commentary

Financials

News

Broker Recommendations